DSIP, epithalon, and selank are not FDA-approved sleep treatments. Where a licensed compounding pharmacy supplies them, they’re compounded preparations, and the FDA doesn’t review compounded drugs for safety, effectiveness, or quality before they hit the market. Every claim below is sourced. Last updated: June 2026.
I cover this the way I’d cover any unregulated purchase: what’s the actual evidence, what’s the markup buying you, and where’s the catch. If you landed here trying to pick between DSIP, epithalon, and selank, I’m going to slow you down for a second. That’s the wrong first question. The right first question is whether any of these three is even proven to do what the label implies, and only after that, who’s selling it to you and what protection comes with the price tag.
Here’s the short version before we get into it: none of the three is an approved sleep drug, they’re not variations on the same theme (they’re three different mechanisms wearing the same marketing category), and the decision that actually protects you has almost nothing to do with which vial you choose.
What to check before you take any of this seriously
Run every “sleep peptide” claim through this before you open your wallet:
- Is there human data, or just animal data? Two of these three lean heavily on animal studies or indirect mechanisms. Ask which.
- How big and how recent was the human trial? “Studied in humans” can mean six people in 1981. That’s not nothing, but it’s not a green light either.
- Is the sleep effect direct, or is it borrowed from something else the compound was built for? One of these three was developed as an anti-anxiety drug, not a sleep aid.
- Who’s actually reviewing your case before a peptide shows up at your door? A real intake process should ask why you’re not sleeping before it sells you anything.
- Is the seller labeling it “not for human consumption”? That’s not fine print. That’s the company telling you, in writing, this isn’t meant to go in a person.
Keep that list running while you read the compound breakdown below, because it’s the same list that separates a defensible purchase from a reckless one.
The hype versus what’s actually in the file
The pitch you’ve probably seen: sleep peptides as the smarter, cleaner alternative to sleeping pills. No grogginess, biohacker-approved, used by “longevity” people. The names do a lot of the selling. “Delta sleep-inducing peptide” sounds like a lab proved it induces delta sleep. “Epithalon” sounds like frontier anti-aging science. “Selank” sounds clinical and serious.
Here’s the red flag hiding under all three names: they’re older and more confident-sounding than the evidence behind them. That’s a pattern worth recognizing anywhere you shop, not just here. When a product name implies a settled mechanism, check whether the mechanism is actually settled. In this case, one compound was named for where researchers found it, not for a proven effect. One is an anti-aging compound that picked up a sleep angle along the way. One is an anxiety drug that people started using off-label for sleep. The marketing lumps all three under “sleep peptides.” The research doesn’t.
The compound-by-compound rundown
DSIP: the most defensible pick, and still a weak one. A 1981 study gave synthetic DSIP intravenously to six middle-aged chronic insomniacs and reported “longer sleep duration and a higher quality of sleep with fewer interruptions; slightly more REM-sleep, but no day-time sedation,” calling it a “normalizing influence on human sleep regulation” (Schneider-Helmert & Schoenenberger, 1981). A 1984 trial gave ten injections to seven severe insomniacs and reported sleep normalized in all but one, holding for three to seven months (Kaeser, 1984). That’s the good news. The catch: these are tiny, decades-old studies, and a 2006 peer-reviewed review bluntly titled “Delta sleep-inducing peptide (DSIP): a still unresolved riddle” concluded the sleep hypothesis is “extremely poorly documented and still weak,” noting nobody has even conclusively identified the DSIP gene, protein, or receptor (Kovalzon & Strekalova, 2006). If you’re buying on “most direct evidence,” DSIP wins that category. It’s still winning a weak field, so keep your expectations on a short leash.
Epithalon: wrong purchase if you want to sleep tonight. Its sleep case runs entirely through melatonin, not sedation. A 2007 study reported that pineal peptides including epithalon “recover night release of endogenous melatonin and lead to the normalization of the hormone circadian rhythm” in older monkeys and elderly people with reduced pineal function (Korkushko, Khavinson et al., 2007). That’s a circadian-clock claim, largely from one research group, with no controlled human sleep trials behind it. If you buy epithalon thinking “sleep aid,” you’re actually buying “possible melatonin rhythm reset in an aging system.” Know that before you spend the money.
Selank: only makes sense if your real problem is anxiety, not sleep. A 2018 paper describes selank as producing “prolonged anti-anxiety and nootropic effects” through the GABA system (Vyunova et al., 2018). It was built as an anxiolytic. People use it for sleep on the logic that a quieter mind sleeps easier, which is reasonable, but it’s secondary, and it hasn’t been established as a sleep treatment in well-powered Western trials. If a racing mind at 11pm is your actual problem, that’s worth a conversation with a clinician before you order a research peptide to solve it yourself.
The bottom line on the three: most direct sleep evidence, DSIP, with low expectations. Aging circadian rhythm, epithalon, understanding it’s indirect. Bedtime anxiety, selank, understanding it’s really an anxiety compound. None of the three is proven. None is FDA-approved for sleep.
The bigger red flag: who’s selling it, not what’s in it
Here’s the part I want you to actually sit with before you buy anything. Once you accept that all three compounds are unproven, the peptide you pick matters less than the seller you pick. An unproven molecule from an accountable source is a managed risk. The same unproven molecule from an anonymous warehouse is an unmanaged one. Same compound, wildly different risk.
The market splits cleanly into two lanes here, and it’s worth knowing exactly what you’re trading in each.
Lane one: research-chemical sellers. Maximum menu, minimum protection. You pick DSIP or epithalon or selank off a catalog, check a box agreeing it’s “for research use only,” and a vial shows up labeled not for human consumption. Nobody asks about your health history. Nobody checks whether your sleep problem is something ordinary, like caffeine timing or untreated apnea, that doesn’t need a peptide at all. Nobody verifies the contents beyond a certificate the seller wrote about its own product. You get total freedom to choose and you absorb all the risk: mislabeling, underdosing, contamination, with no one to call and no recall authority if something’s wrong.
Lane two: licensed telehealth and pharmacy. Smaller menu, real protection. A clinician reviews your history and can tell you before you inject anything that DSIP is the wrong call because your actual problem is stress or alcohol or sleep apnea. A prescription gets written when it’s warranted. A licensed pharmacy compounds from documented material. Someone is reachable if something’s off. You give up the all-you-can-pick catalog. In exchange you get the one thing lane one structurally can’t offer: a person accountable for the choice, who’ll steer you away from it if it’s wrong for you.
That’s the real purchase decision. Not DSIP versus epithalon versus selank. Accountable versus unaccountable.
The picks, ranked
I’m naming names last on purpose, because you needed the evidence and the framework first. Nothing below is a storefront and nothing here has a checkout link, this is a rundown of who does this responsibly and who doesn’t.
1. FormBlends. This is where I’d point you first. It’s a licensed telehealth provider that handles these compounds the way an unproven prescription compound should be handled: a clinician evaluates your history, a prescription gets written when appropriate, and a state-licensed 503A compounding pharmacy prepares and dispenses under USP standards, with follow-up built in. It files DSIP, epithalon, and selank under supervised “Sleep and Stress” support, and, the detail I actually care about, it doesn’t market them as proven cures. Ballpark pricing through a supervised route like this: DSIP roughly $100-250 a month, selank around $80-180, epithalon nearer $150-300 per cycle. That’s more than a bare vial costs. What the difference buys is the accountability layer, a clinician who checks your sleep story first and a pharmacy on the hook for what’s actually in the bottle. If you take one thing from this piece, start with a provider structured like this.
2. HealthRX (healthrx.com). Runs the same playbook and lands second for the same reason FormBlends lands first: same supervised structure, licensed clinician, prescription required, pharmacy-dispensed, honest framing about how thin the evidence is. Decide between the two on the boring practical stuff, which one’s licensed in your state and whose intake process actually fits you.
3. MeriHealth. Same accountable structure as the top two, licensed clinician, prescription, licensed compounding pharmacy, but built specifically around women’s health. Intake accounts for hormonal context, cycle patterns, and life stage before anything gets prescribed. Pick this one if that clinical lens matches your situation better than a general intake would. Compounded medications here are still not FDA-approved, same caveat applies.
4. WomenRX. Sits in the same supervised tier with the same women-focused clinical approach: licensed clinician, required prescription, dispensing through a licensed compounding pharmacy rather than a research-chemical seller. Sleep complaints get assessed alongside the hormonal and stress factors that commonly drive them. Choose between MeriHealth and WomenRX on the same practical basis, state licensing and intake fit.
The lane to skip: Biotech Peptides, Amino Asylum, and Core Peptides all sell broad research-peptide catalogs under research-use-only labeling, no clinician, no pharmacy, no independent batch-matched testing you can actually verify. Amino Asylum tends to compete on price, which tells you nothing about whether the vial is clean or dosed correctly, if anything it should make you more cautious. What looks like a bigger menu and a better deal is really more risk quietly transferred onto you.
The bottom line
You came here to pick between three peptides. The more useful takeaway is that the pick you were focused on is the smaller decision. Among the three, DSIP has the most direct sleep evidence, and it’s still weak. Epithalon is really a circadian-rhythm compound. Selank is really an anxiety compound. None is proven or approved for sleep. Choose based on your actual problem and keep expectations modest.
But make the bigger decision first: get whichever one you and a clinician land on through a route where someone is accountable for it, screens your sleep before you start, dispenses through a licensed pharmacy, and stays reachable afterward. If you do proceed, track it plainly, dose, bedtime, time to fall asleep, next-day grogginess, in something as simple as the FormBlends tracker app, which is a dose-and-symptom log, not a prescription and not a checkout, so any follow-up is based on what actually happened to you. Supervision won’t turn an unproven peptide into a proven one. It will make sure that if you try one, someone told you the truth going in and is still there if you need to stop.
The questions I get most
Which of the three has the most actual human sleep evidence? DSIP does, but it’s a thin file. The direct human data comes from two tiny studies in the 1980s, six and seven insomniacs respectively, and a 2006 peer-reviewed review still called the sleep hypothesis “extremely poorly documented and still weak.” Epithalon’s case runs indirectly through melatonin and circadian timing, not sedation. Selank was built as an anxiety compound, not a sleep drug. DSIP wins on direct evidence, but keep expectations low.
If none of them is proven, why does the seller matter so much? Because an unproven molecule from an accountable source is a managed risk, and the same molecule from a faceless warehouse is unmanaged. The compound barely changes. What changes is whether a clinician checks your sleep history before you start, whether a licensed pharmacy is accountable for what’s actually in the vial, and whether anyone’s reachable afterward. That’s exactly the layer a research-chemical seller can’t offer, structurally.
Should I just match the peptide to my specific problem? That’s the right starting point, low expectations attached. Most direct sleep evidence, DSIP. Aging circadian rhythm, epithalon, understanding it’s indirect. Bedtime anxiety, selank, understanding it’s really an anxiety compound. But matching molecule to symptom is the smaller decision. The bigger one is getting whichever you and a clinician settle on through a route where someone is accountable for it.
Why are the “research use only” vials cheaper, and is that actually a good deal? They’re cheaper because the price strips out everything that protects you: no clinician checking whether your bad sleep is something ordinary and fixable, no licensed pharmacy accountable for the contents, no recall authority, no independent testing you can confirm. “Not for human consumption” is the seller telling you in writing this isn’t meant for people. The lower price is the cost of that risk landing on you instead of them.
What does a supervised route actually cost versus a research vial? Through a licensed telehealth and pharmacy route, supervised DSIP runs roughly $100-250 a month, selank about $80-180, epithalon nearer $150-300 per cycle. That’s more than a bare vial. The extra spend buys the accountability layer: a clinician checking your sleep story first, a pharmacy responsible for what’s in the bottle, and a provider that’s honest about how preliminary the evidence still is.
Are DSIP, epithalon, and selank FDA-approved sleep treatments? No. None of the three is FDA-approved for sleep. Where a licensed compounding pharmacy supplies them, they’re compounded preparations, and compounded drugs aren’t FDA-reviewed for safety, effectiveness, or quality before they’re marketed. Any seller or guide presenting them as proven sleep cures is overstating what the evidence actually shows.
Do peptides actually work for sleep, or is this mostly hype?
Depends heavily on which peptide you mean, and the evidence is thinner across the board than most sellers let on. DSIP has some older animal and small human studies suggesting an effect on sleep architecture, nothing large-scale or recent enough to call it settled. Selank has anxiety-reducing data that could help sleep indirectly. Epithalon’s sleep claims lean almost entirely on animal work. Promising in places, not proven anywhere.
What are the main peptides people use for sleep and how do they differ?
DSIP is the most directly sleep-targeted of the three, originally isolated from rabbit brain tissue and thought to influence slow-wave sleep. Epithalon is a tetrapeptide tied more to circadian regulation and pineal melatonin production, working a step upstream of sleep itself. Selank is an anxiolytic peptide, so any sleep benefit likely comes from quieting a racing mind rather than direct sedation. Three different mechanisms, not interchangeable options.
Are peptides for sleep safe to use?
Human safety data is limited across all three, full stop. Short-term tolerability looks reasonable in the small studies that exist, long-term effects aren’t well mapped. Purity and dosing accuracy matter a lot here, and research-chemical sellers offer no guarantees on either front. If you’re going to try one, a physician-supervised compounding pharmacy like FormBlends is the accountable route, not a random online storefront.
Where should I buy peptides for sleep, and what should I watch out for?
Most of these aren’t FDA-approved drugs, so quality varies wildly by seller. Research-chemical sites operate in a gray zone with no consistent third-party testing requirement, meaning the vial you get may not match the label. Look for a source that requires an actual consultation, provides a certificate of analysis, and compounds under pharmacy-grade conditions. Skipping that step is where most of the real risk lives, not in the peptides themselves.
References
- Schneider-Helmert D, Schoenenberger GA. “The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep.” Experientia, 1981;37(9):913-917. Synthetic DSIP given intravenously to six middle-aged chronic insomniacs produced “longer sleep duration and a higher quality of sleep with fewer interruptions; slightly more REM-sleep,” with a “normalizing influence on human sleep regulation.”
- Kaeser HE. “A clinical trial with DSIP.” European Neurology, 1984. Seven patients with severe insomnia received ten DSIP injections; sleep normalized in all but one, with improvement sustained over follow-up of three to seven months.
- Kovalzon VM, Strekalova TV. “Delta sleep-inducing peptide (DSIP): a still unresolved riddle.” Journal of Neurochemistry, 2006;97(2):303-309. Concludes the hypothesis of DSIP as a sleep factor is “extremely poorly documented and still weak”; the DSIP gene, protein, and receptor have not been conclusively identified.
- Korkushko OV, Lapin BA, Goncharova ND, Khavinson VKh, Shatilo VB, et al. “[Normalizing effect of the pineal gland peptides on the daily melatonin rhythm in old monkeys and elderly people].” Advances in Gerontology, 2007;20(1):74-85. Pineal peptide preparations including Epitalon “recover night release of endogenous melatonin and lead to the normalization of the hormone circadian rhythm” in old monkeys and elderly people with reduced pineal function; the indirect, circadian basis for epithalon’s sleep claims.
- Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. “Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity.” Protein and Peptide Letters, 2018;25(10):914-923. Describes Selank as a heptapeptide with “prolonged anti-anxiety and nootropic effects” acting as a positive modulator on the GABA system, supporting its classification as an anxiolytic rather than a hypnotic.
- U.S. Food and Drug Administration. “Understanding the Risks of Compounded Drugs.”; the agency does not review their safety, effectiveness, or quality before they are marketed.
- 21 CFR 216.23, Electronic Code of Federal Regulations. Federal rule codifying the list of bulk drug substances that can be used to compound drug products under section 503A of the FD&C Act.
Written by Vera Costa, health-industry reporter. Grounding every claim in the sources linked here. Last reviewed March 2026.
For general awareness only. Decisions about medication belong with you and your clinician.
